RE: CIZ1B12 May 2022 18:14
Monthly cashburn here should be very low right now, especially considering that as per RNS any funding requirements to bring the lung cancer blood test to market including, testing, manufacture, distribution and sales are to be covered by Chinese partners, yet we benefit from the 10% Royalty agreement, which considering this was reached in February and the company is looking at 'near term revenue' then we could hear something literally any day now.
Lot's of investor's have preciously backed the CIZ1B biomarker for research and development all the way from 2005 to the point this became a listed company.
The partners we also have aboard are big players - "iCCAMT backers include German Medical Valley, Robert Bosch GmbH and Sinopharm Group"
So the product is good, otherwise the Chinese and now the US wouldn't be interested, so it's definitely a stonking hold for those that have the nerve to keep holding for potentially really decent returns down at this level.
The markets have been crap today everywhere and we have actually faired quite well considering.